-- Appointment Brings 30 Years of Strategic Advisory and
Capital Markets Experience
-- OncoCyte is Advancing Three Non-invasive Cancer Diagnostics
Through Clinical Trials
OncoCyte Corporation, a cancer diagnostics company and a member of the
BioTime, Inc. (NYSE MKT:BTX) family of companies, announced today that
Andy Arno has been appointed to the Company’s Board of Directors.
Andy Arno, 56, brings to OncoCyte a wealth of knowledge from his 30
years of capital markets experience working with emerging growth
companies. He is currently Vice Chairman of “The Special Equities Group”
at Chardan Capital Markets, LLC, a privately held investment banking
firm. He was previously Managing Director of Emerging Growth Equities,
an investment bank, and Vice President of Sabr, Inc., as well
as President of LOMUSA Limited, an investment banking firm. From 2009 to
2012, Andy served as Vice Chairman and Chief Marketing Officer of
Unterberg Capital, LLC, an investment advisory firm that he co-founded.
He also served as Vice Chairman and Head of Equity Capital Markets of
Merriman Capital LLC, an investment banking firm, and served on the
board of its parent company, Merriman Holdings, Inc. Mr. Arno currently
serves on the boards of Asterias Biotherapeutics (NYSE MKT:AST) and
Smith Micro Software, Inc., and is a graduate of George Washington
University.
“OncoCyte is uniquely positioned to advance in the non-invasive
diagnostic market targeting lung, breast and bladder cancer. Andy’s
wealth of experience in the capital markets and advising emerging growth
companies will be invaluable as we develop and execute strategies to
fund OncoCyte’s development and growth. We look forward to having Andy
Arno assist us with his vision, leadership and expertise in support of
the Company’s mission as we build our diagnostic product pipeline and
team,” said William Annett, OncoCyte’s Chief Executive Officer.
About OncoCyte’s Cancer Diagnostics Program
Positive clinical results from two prospective clinical studies of PanC-Dx™
were presented at the annual meeting of the American Association for
Cancer Research (AACR) in April 2015. PanC-Dx™ is OncoCyte’s
class of proprietary, non-invasive cancer diagnostic tests. The AACR
presentation featured the high levels of sensitivity and specificity
demonstrated for PanC-Dx™ when used for the non-invasive
detection of the most common type of bladder cancer, urothelial
carcinoma (UC). These clinical results were announced in collaboration
with investigators from a Leading Medical Institution.
In addition, initial data from a large, prospective clinical study
showed the potential of PanC-Dx™ as a non-invasive, blood-based
diagnostic test to screen for multiple types of human cancers, including
breast cancer. The early data revealed the utility of the protein
Collagen Type X (COL10A1) in distinguishing patients with malignant
breast lesions from those with negative findings. The clinical data were
presented in April 2015 at the annual meeting of the American
Association for Cancer Research (AACR).
About OncoCyte Corporation
OncoCyte, a majority-owned subsidiary of BioTime, Inc., is developing
novel products for the diagnosis and treatment of cancer in order to
improve the quality and length of life of cancer patients. Based on
large unmet need, market size, and data generated thus far from patient
sample screening, OncoCyte is initially focusing its efforts on
developing non-invasive diagnostic products for use in detecting lung,
bladder, and breast cancers. OncoCyte is developing a class of
non-invasive cancer diagnostics based on a proprietary set of cancer
markers characterized, in part, by broad gene expression patterns in
numerous cancer types. The Company’s biomarkers were discovered
as a result of ongoing research within OncoCyte and BioTime on the gene
expression patterns associated with embryonic development. This research
has demonstrated that many of the same genes associated with normal
growth during embryonic development are abnormally reactivated by cancer
cells. These genes regulate such diverse processes as cell
proliferation, cell migration, and blood vessel formation. Many of these
genes have not been previously associated with cancer. Moreover,
expression of a large subset of these genes is conserved across numerous
cancer types (e.g., cancers of the breast, colon, ovaries, etc.),
suggesting that these genes may control fundamental processes during
cancer growth and progression. In addition to their potential value in
developing diagnostic biomarkers, an understanding of the pattern of
expression of these genes may also enable the development of powerful
new cancer therapeutics that target rapidly proliferating cancer cells.
About BioTime
BioTime, Inc., a pioneer in regenerative medicine, is a clinical-stage
biotechnology company. BioTime and its subsidiaries are leveraging their
industry-leading experience in pluripotent stem cell technology and a
broad intellectual property portfolio to facilitate the development and
use of cell-based therapies and gene marker-based molecular diagnostics
for major diseases and degenerative conditions for which there presently
are no cures. The lead clinical programs of BioTime and its subsidiaries
include OpRegen®, currently in a Phase I/IIa trial for
the treatment of the dry form of age-related macular degeneration; AST-OPC1,
currently in a Phase I/IIa trial for spinal cord injuries; Renevia™,
currently in a pivotal trial in Europe as an injectable matrix for the
engraftment of transplanted cells to treat HIV-related lipoatrophy; and PanC-Dx™
cancer diagnostics, nearing the completion of initial clinical studies
for the detection of lung, bladder, and breast cancers. AST-VAC2,
a cancer vaccine, is in the pre-clinical trial stage.
BioTime’s family of companies include the publicly traded Asterias
Biotherapeutics, Inc. (NYSE MKT: AST), developing pluripotent stem
cell-based therapies in neurology and oncology, including AST-OPC1
and AST-VAC2; Cell Cure Neurosciences Ltd., developing stem
cell-based therapies for retinal and neurological disorders, including OpRegen®
for dry-AMD; OncoCyte Corporation, developing non-invasive cancer
diagnostics; LifeMap Sciences, Inc., developing and marketing an
integrated on-line database resource for biomedical and stem cell
research; LifeMap Solutions, Inc., a subsidiary of LifeMap Sciences,
developing mobile health (mHealth) products; ES Cell International Pte
Ltd, which has developed cGMP-compliant human embryonic stem cell lines
that are being marketed by BioTime for research purposes under the ESI
BIO branding program; OrthoCyte Corporation, developing therapies to
treat orthopedic disorders, diseases, and injuries; and ReCyte
Therapeutics, Inc., developing therapies to treat a variety of
cardiovascular and related ischemic disorders.
BioTime common stock is traded on the NYSE MKT under the symbol BTX. For
more information, please visit www.biotimeinc.com
or connect with the company on Twitter,
LinkedIn,
Facebook,
YouTube,
and Google+.
Forward-Looking Statements
Statements pertaining to future financial and/or operating results,
future growth in research, technology, clinical development, and
potential opportunities for BioTime and its subsidiaries, along with
other statements about the future expectations, beliefs, goals, plans,
or prospects expressed by management constitute forward-looking
statements. Any statements that are not historical fact (including, but
not limited to statements that contain words such as “will,” “believes,”
“plans,” “anticipates,” “expects,” “estimates”) should also be
considered to be forward-looking statements. Forward-looking statements
involve risks and uncertainties, including, without limitation, risks
inherent in the development and/or commercialization of potential
products, uncertainty in the results of clinical trials or regulatory
approvals, need and ability to obtain future capital, and maintenance of
intellectual property rights. Actual results may differ materially from
the results anticipated in these forward-looking statements and as such
should be evaluated together with the many uncertainties that affect the
business of BioTime and its subsidiaries, particularly those mentioned
in the cautionary statements found in BioTime’s Securities and Exchange
Commission filings. BioTime disclaims any intent or obligation to update
these forward-looking statements.
To receive ongoing BioTime corporate communications, please click on the
following link to join our email alert list: http://news.biotimeinc.com
View source version on businesswire.com: http://www.businesswire.com/news/home/20150715005487/en/
Copyright Business Wire 2015